Morgan Stanley Upgrades ResMed to Overweight, Announces $169 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Sean Laaman has upgraded ResMed (NYSE:RMD) from Equal-Weight to Overweight and set a price target of $169.
October 27, 2023 | 12:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ResMed's stock has been upgraded by Morgan Stanley from Equal-Weight to Overweight, with a new price target of $169.
The upgrade from Morgan Stanley is a positive signal for ResMed. It indicates that the analyst believes the company's stock is likely to outperform. The new price target of $169 also suggests that the analyst sees significant upside potential for the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100